| Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia M Mori, N Kaneko, Y Ueno, M Yamada, R Tanaka, R Saito, I Shimada, ... Investigational new drugs 35, 556-565, 2017 | 216 | 2017 |
| Binding and aggregation mechanism of amyloid β-peptides onto the GM1 ganglioside-containing lipid membrane T Hoshino, MI Mahmood, K Mori, K Matsuzaki The journal of physical chemistry B 117 (27), 8085-8094, 2013 | 84 | 2013 |
| Formation of GM1 ganglioside clusters on the lipid membrane containing sphingomyeline and cholesterol K Mori, MI Mahmood, S Neya, K Matsuzaki, T Hoshino The journal of physical chemistry B 116 (17), 5111-5121, 2012 | 77 | 2012 |
| Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase K Ohno, K Mori, M Orita, M Takeuchi Current medicinal chemistry 18 (2), 220-233, 2011 | 74 | 2011 |
| The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non–small cell lung cancer model mice M Mori, Y Ueno, S Konagai, H Fushiki, I Shimada, Y Kondoh, R Saito, ... Molecular cancer therapeutics 13 (2), 329-340, 2014 | 67 | 2014 |
| Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations TC Tarver, JE Hill, L Rahmat, AE Perl, E Bahceci, K Mori, CC Smith Blood advances 4 (3), 514-524, 2020 | 64 | 2020 |
| Discovery of N-[2-Hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (Darexaban, YM150) as a Potent and Orally Available … F Hirayama, H Koshio, T Ishihara, S Hachiya, K Sugasawa, Y Koga, ... Journal of medicinal chemistry 54 (23), 8051-8065, 2011 | 39 | 2011 |
| Small-world phenomena in chemical library networks: application to fragment-based drug discovery N Tanaka, K Ohno, T Niimi, A Moritomo, K Mori, M Orita Journal of chemical information and modeling 49 (12), 2677-2686, 2009 | 33 | 2009 |
| Common Semiopen Conformations of Mg2+-Free Ras, Rho, Rab, Arf, and Ran Proteins Combined with GDP and Their Similarity with GEF-Bound Forms K Mori, M Hata, S Neya, T Hoshino Journal of the American Chemical Society 127 (43), 15127-15137, 2005 | 32 | 2005 |
| Aromatic substitution reaction of 2-chloropyridines catalyzed by microsomal glutathione S-transferase 1 K Inoue, T Ohe, K Mori, T Sagara, Y Ishii, M Chiba Drug metabolism and disposition 37 (9), 1797-1800, 2009 | 22 | 2009 |
| Computational analysis of water residence on ceramide and sphingomyelin bilayer membranes Y Imai, X Liu, J Yamagishi, K Mori, S Neya, T Hoshino Journal of Molecular Graphics and Modelling 29 (3), 461-469, 2010 | 17 | 2010 |
| Prediction of the structure of complexes comprised of proteins and glycosaminoglycans using docking simulation and cluster analysis T Takaoka, K Mori, N Okimoto, S Neya, T Hoshino Journal of Chemical Theory and Computation 3 (6), 2347-2356, 2007 | 17 | 2007 |
| Identification of a novel oncogenic mutation of FGFR4 in gastric cancer T Futami, T Kawase, K Mori, M Asaumi, R Kihara, N Shindoh, S Kuromitsu Scientific Reports 9 (1), 14627, 2019 | 16 | 2019 |
| Discovery of N-{2-Methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl}-N′-[2-(propane-2-sulfonyl) phenyl]-1, 3, 5-triazine-2, 4-diamine (ASP3026), a Potent and … K Iikubo, Y Kondoh, I Shimada, T Matsuya, K Mori, Y Ueno, M Okada Chemical and Pharmaceutical Bulletin 66 (3), 251-262, 2018 | 15 | 2018 |
| Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models A Nakayama, T Nagashima, Y Nishizono, K Kuramoto, K Mori, K Homboh, ... British Journal of Cancer 126 (5), 744-753, 2022 | 13 | 2022 |
| Novel strategy to boost oral anticoagulant activity of blood coagulation enzyme inhibitors based on biotransformation into hydrophilic conjugates T Ishihara, Y Koga, K Mori, K Sugasawa, Y Iwatsuki, F Hirayama Bioorganic & Medicinal Chemistry 22 (22), 6324-6332, 2014 | 10 | 2014 |
| Discovery and biological evaluation of 1-{2, 7-diazaspiro [3.5] nonan-2-yl} prop-2-en-1-one derivatives as covalent inhibitors of KRAS G12C with favorable metabolic stability … T Imaizumi, M Akaiwa, T Abe, T Nigawara, T Koike, Y Satake, K Watanabe, ... Bioorganic & Medicinal Chemistry 71, 116949, 2022 | 8 | 2022 |
| A mini-review on chemoinformatics approaches for drug discovery N Kawashita, H Yamasaki, T Miyao, K Kawai, Y Sakae, T Ishikawa, K Mori, ... Journal of Computer Aided Chemistry 16, 15-29, 2015 | 7 | 2015 |
| A study on the role of Mg2+ in a Ras protein by MD simulation K Mori, M Hata, S Neya, T Hoshino Chem-bio informatics journal 2 (4), 147-155, 2002 | 7 | 2002 |
| Integrating Incompatible Assay Data Sets with Deep Preference Learning X Sun, R Tamura, M Sumita, K Mori, K Terayama, K Tsuda ACS Medicinal Chemistry Letters 13 (1), 70-75, 2021 | 2 | 2021 |
Tsukasa IshiharaNational Institute of Advanced Industrial Science and Technology (AIST)Verified email at aist.go.jp
